Skip to main content
SpringerLink
Log in

Quinapril for Treatment of Hypertension in Turkey

Dose Titration and Diuretic Combination Treatment Strategies

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective: Recently the PatenT (Prevalence, awareness, treatment and control of hypertension in Turkey) study showed that while the prevalence of hypertension in Turkey is high, effective control of BP is infrequently achieved. This study investigated the efficacy and safety of quinapril (as monotherapy or in combination with hydrochlorothiazide [HCTZ]) for achieving BP control (target <140/90mm Hg) in Turkish subjects with mild to moderate hypertension.

Methods: Two-hundred male and female outpatients aged 19–65 years with mild to moderate hypertension (stage I or II, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 7 guidelines) entered this 12-week, open-label study. All subjects received quinapril 20 mg/day for 6 weeks. If BP targets were achieved at week 6, responders were maintained on 20 mg/day; if BP targets were not achieved, non-responders were randomised to quinapril 40 mg/day or quinapril 20 mg/day + HCTZ 12.5 mg/day for the remainder of the study.

Results: After 6 weeks, 63% of subjects achieved BP targets, and 82% of week-6 responders who continued on quinapril 20 mg/day maintained BP targets at week 12. Of the non-responders, 50% and 52% randomised to quinapril 40 mg/day or quinapril 20 mg/day + HCTZ 12.5 mg/day, respectively, went on to achieve BP targets by week 12. Safety was not compromised with increased dosages or use of combination therapy.

Conclusion: Quinapril was an effective and safe treatment for achieving and maintaining recommended BP targets in this sample population. These findings will provide clinicians in Turkey with valuable data on the use of quinapril for effective control and management of hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II

Similar content being viewed by others

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–71

    Article  PubMed  CAS  Google Scholar 

  2. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92

    Article  PubMed  Google Scholar 

  3. Volpe M. Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. J Hum Hypertens 2005; 19: 93–102

    Article  PubMed  CAS  Google Scholar 

  4. Wong SYS, McInnes GT, MacDonald TM. Why not prescribe the best drugs for hypertension now? J Hum Hypertens 2003; 17: 505–11

    Article  PubMed  CAS  Google Scholar 

  5. Ohta Y, Tsuchihashi T, Fujii K, et al. Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. J Hum Hypertens 2004; 18: 273–8

    Article  PubMed  CAS  Google Scholar 

  6. Lang T, de Gaudemaris R, Chatellier G, et al. Prevalence and therapeutic control of hypertension in 30,000 subjects in the workplace. Hypertension 2001; 38: 449–54

    Article  PubMed  CAS  Google Scholar 

  7. McInnes GT. How important is optimal blood pressure control? Clin Ther 2004; 26Suppl. A: A3–11

    Article  PubMed  Google Scholar 

  8. Flack J, Yunis C, Preisser J, et al. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) study. ATIME Research Group. Arch Intern Med 2000; 160: 1842–7

    Article  PubMed  CAS  Google Scholar 

  9. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 Suppl.: 1–20

    Article  Google Scholar 

  10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53

    Article  PubMed  CAS  Google Scholar 

  11. Schlaifer JD, Wargovich TJ, O’Neill B, et al. Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators: Trial on Reversing Endothelial Dysfunction. Am J Cardiol 1997; 80: 1594–7

    Article  PubMed  CAS  Google Scholar 

  12. Otsuka M, Yamamoto H, Okimoto T, et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J 2004; 147: 662–8

    Article  PubMed  CAS  Google Scholar 

  13. Pitt B, O’Neill B, Feldman R, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058–63

    Article  PubMed  CAS  Google Scholar 

  14. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–34

    Article  PubMed  CAS  Google Scholar 

  15. Canter D, Frank GJ, Knapp LE, et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril Investigator Group. J Hum Hypertens 1994; 8: 155–62

    PubMed  CAS  Google Scholar 

  16. Williams B. Treating hypertension: it is not how you start but where you end that matters. J Hypertens 2003; 21: 455–7

    Article  PubMed  CAS  Google Scholar 

  17. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  Google Scholar 

  18. Altun B, Arici M, Nergizoglu G, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005; 23: 1817–23

    Article  PubMed  CAS  Google Scholar 

  19. Knapp LE, Frank GJ, McLain R, et al. The safety and tolerability of quinapril. J Cardiovasc Pharmacol 1990; 15Suppl. 2: S47–55

    Article  PubMed  Google Scholar 

  20. Karpov IuA, Deev AD. Russian study of efficacy and safety of an angiotensin converting enzyme inhibitor quinapril in patients with hypertension [in Russian]. Kardiologiia 2003; 43: 28–32

    PubMed  Google Scholar 

  21. Lenz T, Schulte KL, Wagner B, et al. Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. Eur Heart J 1994; 15: 940–6

    PubMed  CAS  Google Scholar 

  22. Romero R, Castellote E, Ocon J, et al. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8

    Article  PubMed  CAS  Google Scholar 

  23. Pueyo C, Diaz C, Sol J, et al. Efficacy and safety of quinapril 40mg once daily as monotherapy for patients with poorly controlled hypertension: the EUREKA study. Clin Drug Invest 2000; 20: 81–8

    Article  CAS  Google Scholar 

  24. Manzato E, Capurso A, Crepaldi G. Modification of cardiovascular risk factors during antihypertensive treatment: a multicentre trial with quinapril. J Int Med Res 1993; 21: 15–25

    PubMed  CAS  Google Scholar 

  25. Frishman W. The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension. Clin Cardiol 1990; 13(Suppl; 7): 19–25

    Google Scholar 

  26. Physicians’ Desk Reference [online]. Available from URL: http://www.pdr.net

  27. Nalbantgil I, Nalbantgil S, Ozerkan F, et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract 2004; Suppl.: 50-4

  28. Mutlu H, Ozhan H, Okcun B, et al. The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy. Blood Press 2002; 11: 53–5

    Article  PubMed  CAS  Google Scholar 

  29. Kavgaci H, Sahin A, Onder Ersoz H, et al. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract 2002; 58: 19–25

    Article  PubMed  CAS  Google Scholar 

  30. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46

    Google Scholar 

  31. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393–404

    Article  Google Scholar 

  32. Culy CR, Jarvis B. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002; 62: 339–85

    Article  PubMed  CAS  Google Scholar 

  33. Weir MR. Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension. J Hum Hypertens 1994; 8: 725–30

    PubMed  CAS  Google Scholar 

  34. Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of anti-hypertensive drugs. J Hypertens 2002; 20: 771–7

    Article  PubMed  Google Scholar 

  35. Grimm RH, Margolis KL, Papademetriou V, et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). Hypertension 2001; 37: 19–27

    Article  PubMed  CAS  Google Scholar 

  36. Pfizer Inc. Accupril® (quinapril hydrochloride tablets): product information 2003 [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_accupril.pdf [Accessed 2007 Jul 1]

  37. Kroke A, Bergmann M, Klipstein-Grobusch K, et al. Obesity, body fat distribution and body build: their relation to blood pressure and prevalence of hypertension. Int J Obes Relat Metab Disord 1998; 22: 1062–70

    Article  PubMed  CAS  Google Scholar 

  38. Ram C. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6: 569–77

    Article  CAS  Google Scholar 

  39. Cohen JS. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians’ Desk Reference. Arch Intern Med 2001; 161: 880–5

    Article  PubMed  CAS  Google Scholar 

  40. Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician 2005; 71: 2089–90

    PubMed  Google Scholar 

  41. Lowry KP, Dudley TK, Oddone EZ, et al. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother 2005; 39: 1198–203

    Article  PubMed  Google Scholar 

  42. Ch Yiannakopoulou E, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243–9

    Article  Google Scholar 

Download references

Acknowledgements

This study was funded by Pfizer. The authors would like to thank all the study team members from Pfizer Turkey and the Asia Biometrics Centre (ABC), Pfizer Worldwide Development Operations, Sydney, Australia for their invaluable contributions to the study design, conduct and reporting. The authors also thank Andrea Malcolm of the ABC for assistance with medical writing of this manuscript. In addition, the authors and study team extend their gratitude to the investigators for their substantial contribution to this study and to the subjects who participated. Dr Wing Lowe is an employee of ABC; the other authors have no conflicts of interest that are directly relevant to the content of this study. This study was previously presented as a poster at the National Nephrology Hypertension Congress in Turkey on 16 November 2005.

Author information

Authors and Affiliations

  1. Ankara Hospital Internal Medicine Department, Sizin evler sitesi, 3. cadde, numara 4, 06530, Çayyolu Ankara, Turkey

    Gul Yener

  2. Family Medicine Department, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

    Sinan Aran

  3. Endocrinology Department, Dicle University Medical Faculty, Diyarbakir, Turkey

    Mithat Bahceci

  4. Cardiology Department, Selcuk University Meram Medical Faculty, Konya, Turkey

    Kurtulus Ozdemir

  5. Cardiology Department, Cumhuriyet University Medical Faculty, Sivas, Turkey

    Fusun Gultekin

  6. Asia Biometrics Centre, Pfizer Worldwide Development Operations, Sydney, Australia

    Wing Lowe

Authors
  1. Gul Yener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sinan Aran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mithat Bahceci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kurtulus Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fusun Gultekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wing Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gul Yener.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yener, G., Aran, S., Bahceci, M. et al. Quinapril for Treatment of Hypertension in Turkey. Clin. Drug Investig. 27, 613–622 (2007). https://doi.org/10.2165/00044011-200727090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200727090-00003

Keywords

Search

Navigation